Is your content IRB approved?

Yes - all of our content for clinical trials is IRB approved. We guarantee IRB approval and historically have a 100% success rate. Speed of approval wholly depends on IRB. Non-clinical trial (general education) content does not need IRB approval.

Other FAQs

What sets your company apart, and how does your process differ from other patient education companies?

PRIMR’s approach to ensuring low-risk content approval by IRBs involves rigorous processes and adherence to regulatory standards. With a track record of 100% IRB approval on first submission for our content over 4 years, PRIMR demonstrates its commitment to compliance and quality assurance. PRIMR employs thorough review processes, collaboration with key opinion leaders in our network, and adherence to industry best practices to achieve consistent approval rates. Other content vendors lack oncology expertise, outsource expert review, slowing down the process, increasing costs and lowering the ultimate quality of the product and impact on patient understanding.

What if I need content on a subject that is not yet in the PRIMR library?

At this stage we are handling specific content requests case by case. Content requests for for a specific drug, device or institution may be fulfilled for a fee.

How do you ensure that the content you create reaches the intended audience effectively?

PRIMR ensures effective reach and addresses lopsided demographics in clinical trials through strategic geo-targeted ads and multilingual content creation. By tailoring content distribution to specific geographic regions and providing multilingual materials, PRIMR aims to enhance trial awareness among diverse populations, thus promoting better representation in clinical trials.